Andrew Hall
Chief Executive Officer at IMV INC.
Net worth: 12 $ as of 31/12/2023
Profile
Andrew Hall is currently the Chief Executive Officer & Director at IMV, Inc. He previously worked as an Executive Director of Business Development at Celgene Corp.
and as an Executive Director of Global Women's Health at Merck & Co., Inc. Mr. Hall completed his undergraduate degree at the University of Melbourne and his graduate degree at RMIT University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMV INC.
0.05% | 20/03/2023 | 6,100 ( 0.05% ) | 12 $ | 31/12/2023 |
Andrew Hall active positions
| Companies | Position | Start |
|---|---|---|
| IMV INC. | Chief Executive Officer | 04/08/2021 |
Former positions of Andrew Hall
| Companies | Position | End |
|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| CELGENE | Corporate Officer/Principal | - |
Training of Andrew Hall
| University of Melbourne | Undergraduate Degree |
| RMIT University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| IMV INC. | Health Technology |
| Private companies | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Stock Market
- Insiders
- Andrew Hall
